drugset / Trial / NCT05127811
A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase I dose-escalation, open-label, multicenter study to assess the safety, tolerability, clinical activity, and pharmacokinetics (PK) of ZN-d5 in Chinese subjects with non-Hodgkin lymphoma (NHL).
Timeline
- Start
- 2021-10-21
- Primary completion
- 2023-05-26
- Completion
- 2023-05-26
Outcome
Outcome not reported
Stopped: “Sponsor's decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZN-d5 | Unknown | 100 mg | — |
| Subject | ZN-d5 | Unknown | 200 mg | — |
| Subject | ZN-d5 | Unknown | 400 mg | — |
| Subject | ZN-d5 | Unknown | 600 mg | — |
| Subject | ZN-d5 | Unknown | 800 mg | — |